Skip to content

Studying the Impact of a Medication Use Evaluation by the Community Pharmacist

Studying the Impact of a Medication Use Evaluation by the Community Pharmacist

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03179722
Acronym
SIMENON
Enrollment
453
Registered
2017-06-07
Start date
2016-11-08
Completion date
2018-10-30
Last updated
2019-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging

Keywords

Aging, Drug-related problems, Medication review, Community pharmacist, Medication use

Brief summary

In this intervention study, 75 Belgian community pharmacies each recruit 12 patients for an intermediate medication review. For each patient, the identified drug-related problems and subsequent interventions are registered using the PharmDisc classification. In a subset of Dutch speaking patients, a pretest-posttest single group design is used to measure the impact of this review on patient related outcomes using questionnaires. The primary outcome is the medication related quality of life, measured via the living with medicines questionnaire. Other patient reported outcomes include adherence, self-management, patient satisfaction, fall incidents and use of emergency healthcare services. Medication records are also collected to objectively measure adherence before and after the intervention.

Interventions

BEHAVIORALMedication review

The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.

BEHAVIORALAdditional data collection: questionnaires

Pre-post study design. At three timepoints, data is collected: * before the medication review (T-1week) * during the review (Tweek 3) * after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management

Sponsors

Association of Belgian Pharmacies (APB)
CollaboratorUNKNOWN
Joke Wuyts
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Parallel group intervention study. In a subset of 140 patients, a pre-post study design is used.

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients should be 70 years or older * Use five or more drugs on a regular basis (prescription or non-prescription drugs) * Live in the ambulatory setting * Obtain his medication from this pharmacy on a regular basis

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Drug-related problems & interventionsOne timeframe: during the medication reviewUsing the validated PharmDisc classification tool
Change in medication related quality of lifeThree timepoints: Before the review, during review (week 3), after the review (week 12)using the Living with medicines questionnaire

Secondary

MeasureTime frameDescription
Change in adherence9 months before and after the interventionusing dispensing data
Change in self-managementTwo timepoints: Before the review, after the review (week 12)using the PAM questionnaire
Change in use of emergency healthcare services & fall incidentsTwo timepoints: Before the review, after the review (week 12)using own questions
Satisfaction with the new serviceOne timepoint: during the review (week 3)Using the PSPSQ2 questionnaire

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026